HK1258757A1 - 4H-吡唑並[1，5-α]苯並咪唑類化合物的鹽型、晶型及其製備方法和中間體 - Google Patents

4H-吡唑並[1，5-α]苯並咪唑類化合物的鹽型、晶型及其製備方法和中間體

Info

Publication number
HK1258757A1
HK1258757A1 HK19101057.7A HK19101057A HK1258757A1 HK 1258757 A1 HK1258757 A1 HK 1258757A1 HK 19101057 A HK19101057 A HK 19101057A HK 1258757 A1 HK1258757 A1 HK 1258757A1
Authority
HK
Hong Kong
Prior art keywords
type
pyrazolo
alpha
preparation
benzimidazole compound
Prior art date
Application number
HK19101057.7A
Other languages
English (en)
Inventor
Xuehai Wang
Charles Z Ding
Jie Shen
Shuhui Chen
Lie Li
Gang Li
Yong Xu
Cailin Wang
Ronghua Tu
Jimeng Wang
Yang Yue
Biao Deng
Hailiang Chen
Hui Liu
Wenjie Sun
Cong Wang
Lu Huang
Zheng Wang
Weidong Li
Original Assignee
Hubei Bio Pharmaceutical Industrial Tech Institute Inc
Humanwell Healthcare Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hubei Bio Pharmaceutical Industrial Tech Institute Inc, Humanwell Healthcare Group Co Ltd filed Critical Hubei Bio Pharmaceutical Industrial Tech Institute Inc
Publication of HK1258757A1 publication Critical patent/HK1258757A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
HK19101057.7A 2015-09-30 2019-01-22 4H-吡唑並[1，5-α]苯並咪唑類化合物的鹽型、晶型及其製備方法和中間體 HK1258757A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510643088 2015-09-30
PCT/CN2016/100821 WO2017054755A1 (zh) 2015-09-30 2016-09-29 4H-吡唑并[1, 5-α]苯并咪唑类化合物的盐型、晶型及其制备方法和中间体

Publications (1)

Publication Number Publication Date
HK1258757A1 true HK1258757A1 (zh) 2019-11-22

Family

ID=58422684

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19101057.7A HK1258757A1 (zh) 2015-09-30 2019-01-22 4H-吡唑並[1，5-α]苯並咪唑類化合物的鹽型、晶型及其製備方法和中間體

Country Status (12)

Country Link
US (2) US10428073B2 (zh)
EP (1) EP3357925B1 (zh)
JP (1) JP6858762B2 (zh)
KR (1) KR102664193B1 (zh)
CN (1) CN108137598B (zh)
AU (1) AU2016333293B2 (zh)
CA (1) CA3003122C (zh)
ES (1) ES2901152T3 (zh)
HK (1) HK1258757A1 (zh)
IL (1) IL258451B (zh)
TW (1) TWI716463B (zh)
WO (1) WO2017054755A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3003122C (en) * 2015-09-30 2023-10-03 Medshine Discovery Inc. Salt type and crystal type of 4h-pyrazolo[1, 5-alpha]benzimidazole compound and preparation method and intermediate thereof
WO2018192445A1 (zh) * 2017-04-17 2018-10-25 广州丹康医药生物有限公司 作为parp抑制活性的多环化合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19920936A1 (de) * 1999-05-07 2000-11-09 Basf Ag Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung
EP1973909A2 (en) * 2005-12-22 2008-10-01 Biogen Idec MA Inc. Transforming growth factor modulators
WO2007144669A1 (en) * 2006-06-15 2007-12-21 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Pyrazolo[1,5-a]quinazolin-5(4h)-ones as inhibitors of poly(adp-ribose)polymerase (parp)
CN101506214A (zh) * 2006-06-20 2009-08-12 艾博特公司 作为parp抑制剂的吡唑并喹唑啉酮
RU2490260C2 (ru) * 2008-03-27 2013-08-20 Янссен Фармацевтика Нв Тетрагидрофенантридиноны и тетрагидроциклопентахинолиноны в качестве ингибиторов parp и ингибиторов полимеризации тубулина
JP6359175B2 (ja) * 2014-04-10 2018-07-18 フーベイ バイオ−ファーマシューティカル インダストリアル テクノロジカル インスティテュート インコーポレイテッド ＰＡＲＰ阻害剤としての４Ｈ‐ピラゾロ［１，５‐α］ベンゾイミダゾール化合物のアナログ
CN104974161B (zh) * 2014-04-10 2019-11-01 湖北生物医药产业技术研究院有限公司 作为PARP抑制剂的4H-吡唑并[1,5-α]苯并咪唑化合物的类似物
CA3003122C (en) * 2015-09-30 2023-10-03 Medshine Discovery Inc. Salt type and crystal type of 4h-pyrazolo[1, 5-alpha]benzimidazole compound and preparation method and intermediate thereof

Also Published As

Publication number Publication date
US20180258093A1 (en) 2018-09-13
IL258451B (en) 2021-03-25
TW201718594A (zh) 2017-06-01
US10428073B2 (en) 2019-10-01
IL258451A (en) 2018-05-31
ES2901152T3 (es) 2022-03-21
AU2016333293A1 (en) 2018-05-10
CN108137598A (zh) 2018-06-08
KR20180083311A (ko) 2018-07-20
JP2018535934A (ja) 2018-12-06
KR102664193B1 (ko) 2024-05-10
CA3003122A1 (en) 2017-04-06
WO2017054755A1 (zh) 2017-04-06
EP3357925A4 (en) 2019-05-01
JP6858762B2 (ja) 2021-04-14
US10941150B2 (en) 2021-03-09
AU2016333293B2 (en) 2020-07-30
TWI716463B (zh) 2021-01-21
US20190375756A1 (en) 2019-12-12
CA3003122C (en) 2023-10-03
EP3357925B1 (en) 2021-10-27
EP3357925A1 (en) 2018-08-08
CN108137598B (zh) 2021-02-12

Similar Documents

Publication Publication Date Title
EP3564237A4 (en) UREA COMPOUND AND PRODUCTION METHOD AND USE THEREOF
SI3287445T1 (sl) Pirazolonska spojina ali njena sol, postopek priprave le-te, herbicidni sestavek in uporaba le-tega
EP3287444A4 (en) New crystal form of lenvatinib methanesulfonate salt and preparation method thereof
EP3299369A4 (en) Pyrido-azaheterecydic compound and preparation method and use thereof
HK1254055A1 (zh) 製備奧貝膽酸及其衍生物的方法
HK1232229A1 (zh) '- '-硫代核苷的新型化合物及其製備方法、藥物組合物和應用
HK1244278B (zh) 喹唑啉衍生物的鹽及其製備方法
HK1256860A1 (zh) 喹唑啉衍生物的晶體及其製備方法
EP3502103A4 (en) CRYSTALLINE FORM, TYPE OF SALT OF A SUBSTITUTED 2-HYDRO-PYRAZOLE DERIVATIVE AND PREPARATION METHOD THEREOF
HRP20200104T8 (hr) Novi heterociklični spoj, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto
EP3378868A4 (en) 6'-SIALYL LACTOSE SODIUM SALT CRYSTAL AND PROCESS FOR PRODUCING THE SAME
EP3369733A4 (en) Crystal form of 4h-pyrazolo[1,5- ]benzoimidazole compound, preparation method therefor and intermediate thereof
PL3330267T3 (pl) Sól pochodnej chinazoliny lub jej kryształ oraz sposób wytwarzania soli pochodnej chinazoliny lub jej kryształu
HK1258757A1 (zh) 4H-吡唑並[1，5-α]苯並咪唑類化合物的鹽型、晶型及其製備方法和中間體
EP3269710A4 (en) Nintedanib diethanesulfonate salt crystal and preparation method and use thereof
HK1252375A1 (zh) 喹唑啉衍生物的晶體及其製備方法
IL254597A0 (en) Crystalline form of ahu377, method for its preparation and use
HUE059444T2 (hu) Morfolinszármazék sója és ennek kristályformája, valamint ezek elõállítási eljárása, gyógyszerkészítménye és alkalmazása
EP3336088A4 (en) CRYSTALLINE FORM OF THE OREXIN RECEPTOR ANTAGONIST COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF
SG11201708692WA (en) Salt form, crystal form and intermediate of 1,2,5-thiadiazolidine-1,1-dioxide and preparation method thereof
HK1232209A1 (zh) 製備 -乙酰氧基丙酸及其衍生物的方法
ZA201901120B (en) Crystal and salt of nitroimidazole, and manufacturing method thereof
PT3632909T (pt) Sal e forma cristalina de composto de andrografólido modificado e seu método de preparação
EP3517529A4 (en) QUINAZOLINE DERIVATIVE SALT, ITS PREPARATION METHOD AND ITS APPLICATION
TWI562978B (en) Method for preparation of 1,4-cyclohexanedialkanol